

A TO A DEMAND

ORM PTO-1449

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

(use several sheets if necessary)

| SERIAL NO. 10/612,818 | ATTORNEY DOCKET NO. 3352.2.2 | | |
|--------------------------|------------------------------|--|--|
| FILING DATE July 1, 2003 | GROUP ART UNIT 1653 | | |
| APPLICANT(S): Yao Xioi | ng Hu et al. | | |

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS/ SUBCLASS | FILING DATE |
|------------------|----|--------------------|--------------|----------------|--------------------|----------------|
| A) | B1 | 6,096,869 | Aug. 1, 2000 | Stanley et al. | 530/351 | 3/22/96 |
| As | B2 | 5,753,233 | May 19, 1998 | Bleul et al. | 424/204.1 | 6/6/95 |

FOREIGN PATENT DOCUMENTS

| EXAMINER | | DOCUMENT | | | CLASS/ | TRANSL | ATION |
|----------|----|--------------|--------------|-------------|----------------|--------|-------|
| INITIAL | | NUMBER | DATE | COUNTRY | SUBCLASS | YES | NO |
| A | ВЗ | WO 99/10744 | Mar. 4, 1999 | Deutschland | G01N 33/569 | | Х |
| As | B4 | EP 0 594 613 | May 11, 1997 | European | GO1N 33/569 | х | |

NON-PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT (Including Author, Title, Source, and Pertinent Pages |
|---------------------|----|---|
| A | B7 | Park et al., Human papillomavirus type 16 E6, E7, and L1 and type 18 E7 proteins produced by recombinant baculoviruses, Journal of Virological Methods, 45:303-318, 307, 1993 |

Z-YALL CLIENTS:3352 (mpact Diagnostics\3352-2-2\3352-2-2 PAT-FIL-Supp IDS 1449 040708.wpd

| EXAMINER | DATE CONSIDERED | 11/29/04 |
|----------|-----------------|----------|
|----------|-----------------|----------|

FORM PTO-1449

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION **DISCLOSURE STATEMENT**

(use several sheets if necessary)

| SERIAL NO. 10/612,818 | ATTORNEY DOCKET NO. 3352.2.2 |
|--------------------------|---------------------------------|
| FILING DATE July 1, 2003 | GROUP ART UNIT 1653 |
| APPLICANT(S): | Kiong Hu |

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS/ SUBCLASS | FILING DATE |
|---------------------|----|--------------------|---------------|------------------|--------------------|----------------|
| B | A1 | 6,183,746 | Feb. 6, 2001 | Urban et al. | 424/186.1 | 10/9/98 |
| | A2 | 5,932,412 | Aug. 3, 1999 | Dillner et al. | 435/5 | 9/22/97 |
| | А3 | 5,629,161 | May 13, 1997 | Muller et al. | 435/7.1 | 12/23/94 |
| | A4 | 5,629,146 | May 13,1997 | Dillner et al. | 435/5 | 6/25/91 |
| | A5 | 4,777,239 | Oct. 11, 1988 | Schoolnik et al. | 530/326 | 7/10/86 |

FOREIGN PATENT DOCUMENTS

| EXAMINER | | DOCUMENT | | | CLASS/ | TRANSI | ATION |
|----------|----|-------------|---------------|----------|----------------|--------|-------|
| INITIAL | | NUMBER | DATE | COUNTRY | SUBCLASS | YES | NO |
| A | A6 | WO 91/18294 | Nov. 28, 1991 | Sweden | G01N 33/569 | X | |
| B | A7 | EP 0344940 | Dec. 12, 1989 | European | C07K 7/06 | Х | - |
| AY | A8 | WO 87/01375 | Mar. 12, 1987 | France | C07K 15/00 | | Х |

NON-PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT (Including Author, Title, Source, and Pertinent Pages |
|------------------|-----|---|
| BI | A9 | Anonymous, Cervical cancer, NIH Consensus Statement 1996 Apr 1-3; 14(1):1-38. |
| MI | A10 | Arends et al., Aetiology, pathogenesis, and pathology of cervical neoplasia, Journal of Clinical Pathology 1998; 51:96-103. |
| AS/ | A11 | Birdsong G.C., Automated rescreening of Pap smears: what are the implications?, Diagnostic Cytopathology, 1996; 13:283-8. |

| EXAMINER DATE CONSIDERED 11/29/04 |
|-----------------------------------|
|-----------------------------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).



| A | | A12 | Boryslewicz et al., A recombinant vaccinia virus encoding human papillomavirus types 16 and 18 E6 and E7 proteins as immunotherapy for cervical cancer, Lancet 1996; 347:1523-7. |
|---|----|------|---|
| | | A13 | Bryan et al., Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: correlation with virus-like particle, Journal of Med Virology 1997; 53:185-8. |
| | | A14 | Chee et al., Immunologic diagnosis and monitoring of cervical cancers using in vitro translated HPV proteins, Gynecology Oncology 1995; 57:226-231. |
| | | A15 | Clavel et al., DNA-EIA to detect high and low risk HPV genotypes in cervical lesions with E6/E7 primer mediated multiplex PCR, Journal of Clinical Pathology 1998; 51(1):38-43. |
| | / | ∕A16 | Cox et al., Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance, American Journal of Obstetrics and Gynecology 1995; 172:946-54. |
| | | A17 | Cuzick et al., A systematic review of the role of human papilloma virus (HPV) testing within a crevical screening programme: summary and conclusions, British Journal of Cancer 2000; 85(5): 561-65. |
| | / | A18 | Donnelly et al., Protection against papillomavirus with a polynucleotide vaccine, Journal of Infectious Diseases 1996; 713: 314-20. |
| | | A19 | Dreau et al., Human papilloma virus in melanoma biopsy specimens and its relation to melanoma progression, Annals of Surgery 2000; 231(5): 664-71. |
| | | A20 | Ferenczy et al., Diagnostic performance of hybrid capture human papillomavirus deoxyribonucleic acid assay combined with liquid-based cytologic study, American Journal of Obstetrics and Gynecology 1996; 175(3): 651-6. |
| | | A21 | Frisch et al., Human papillomavirus-associated carcinomas in Hawaii and the mainland U.S., Cancer 2000; 88: 1464-9. |
| | | A22 | Fu et al., Human papillomavirus and papillomatosis lesion of female lower genital tract, Infectious Disease Obstetrics and Gynecology 1994; 1: 235-41. |
| | | A23 | Fu et al., Diagnosis between condyloma acuminatum and pseudocondyloma in lower female genital tract as determined by a PCR-based method, Chinese Journal of Obstetrics and Gynecology 1994; 29(1): 168-88. [in Chinese; English abstract] |
| | , | A24 | Gregoire et al., Preferential association of human papillomavirus with high-grade histologic variants of penile-invasive squamous cell carcinoma, Journal of the National Cancer Institute 1995; 87(22): 1705-9. |
| | 11 | A25 | Hagensee et al., Seroprevalence of human papillomavirus type 16 in pregnant women, Obstetrics and Gynecology 1999; 94(5): 653-8. |
| | | | |

| EXAMINER | √ | DATE CONSIDERED | 11/29/24 |
|----------|----------|-----------------|----------|
| · | | | / / |

| OIPE | 2 |
|--------------|--------------|
| FEB 1 3 2004 | 116 3D |
| RADEMARK | 4 |
| | FEB 1 3 2004 |

| 10EVAD | <u> </u> | | |
|--------|----------|-------|---|
| K | カノ | / A26 | Hamsikova et al., Presence of antibodies to seven human papillomavirus type 16 derived peptides in cervical cancer patients and health controls, Journal of Infectious Diseases 1994; 170: 1424-31. |
| | | A27 | Harlan et al., Cervical cancer screening: who is not screened and why?, American Journal of Public Health 1991; 81: 885-91. |
| | / | A28 | Hayward et al., Who gets screened for cervical and breast cancer? Results from a New National Survey, Archives of Internal Medicine 1988; 148: 1117-81. |
| | | A29 | Hu YX, Introduction and prospect of application of biogenetic engineering, Guangzhou Medical Journal 1990; 2:8-10. [in Chinese, English title] |
| | | A30 | Hutchinson et al., Homogeneous sampling accounts for the increased diagnostic accuracy using the ThinPrep [™] Processor, American Journal of Clinical Pathology 1994; 101: 215-9. |
| | | , A31 | Jochmus et al., Detection of antibodies to the E4 or E7 proteins of human papillomaviruses (HPV) in human sera by western blot analysis: type specific reaction of anti-HPV 16 antibodies, Molecular and Cellular Probes 1992; 6: 319-25. |
| | | A32 | Kochel et al., Antibodies to human papillomavirus type-16 in human sera as revealed by the use of prokaryotically expressed viral gene products, Virology 1991; 182: 644-54. |
| | | A33 | Konya et al., Identification of a cytotoxic T-lymphocyte epitope in the human papillomavirus type 16 E2 protein, Journal of General Virology 1997; 78: 2615-20. |
| | | A34 | Lorincz et al., Human papillomavirus infection of the cervix: relative risk associations of 16 common anogenital types, Obstetrics and Gynecology 1992; 79: 328-37. |
| | J | A35 | Lowy et al., Papillomaviruses: prophylactic vaccine prospects, Biochimica et Biophysica Acta 1998; 1423: M1-8. |
| | | A36 | Mellin et al., Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival, International Journal of Cancer (Pred. Oncol.) 2000; 89: 300-4. |
| | | A37 | Meschede et al., Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer, Journal of Clinical Microbiology 1998; 36(2): 475-80. |
| | | A38 | Muller et al., Antibodies to the E4, E6 and E7 proteins of human papillomavirus (HPV) type 16 in patients with HPV-associated disease and in the normal population, Journal of Investigative Dermatology 1995; 104: 138-41. |
| | / | A39 | Nobbenhuis et al., Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study, Lancet 1999; 354: 20-5. |
| | | | |

| EXAMINER | DATE CONSIDERED | 11/29/24 |
|----------|-----------------|----------|

| ż | OIPE | |
|------|--------------|--|
| PATE | FEB 1 3 2004 | |
| K | RACEMENT CH | |

| types 6, 11, 16, 18 and 31 virus-like particles in human immunodeficiency virus-seropositive women, Journal of General Virology 2000; 81: 701-8. A41 Pirog et al., Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma, American Journal of Pathology 2000; 157(4): 1055-62. A42 Rice et al., High risk genital papillomavirus infections are spread vertically, Review of Medical Virology 1999; 9: 15-21. A43 Schiffman MH, Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia, Journal of the National Cancer Institute 1992; 84(6): 394-8. A44 Silins et al., Serological evidence for protection by human papillomarvirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis, Journal of General Virology 1999; 80: 2931-6. A45 Slawson et al., Follow up papanicolau smear for cervical atypia: are we missing significant disease? A HARNET study, Journal of Family practice 1993; 36(3): 289-93. A46 Soini et al., Presence of human papillomavirus DNA and abnormal p53 protein accumulation in lung carcinoma, Thorax 1996; 51: 887-93. A47 Sugase et al., Distinct manifestations of human papillomavirus in the vagina, International Journal of Cancer 1997; 72: 412-5. A48 Sun et al., Serum antibodies to human papillomavirus 16 proteins in women from Brazil with invasive cervical carcinoma, Cancer Epidemiology, Biomarkers & Prevention 1999; 8: 935-40. A49 Verdon ME, Issues in the management of human papillomavirus genital disease, American Family Physician 1997; 55: 1813-16. A50 Walboomers et al., Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, Journal of Pathology 1999; 189: 12-19. A51 Wright et al., HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer, Journal of the American Medical Association 2000; 283: 81-6. A52 Zumbach et al., Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in patients with head-and-ne | | ′ | | |
|--|----|----------|-----|---|
| subtypes of cervical adenocarcinoma, American Journal of Pathology 2000; 157(4): 1055-62. A42 Rice et al., High risk genital papillomavirus infections are spread vertically, Review of Medical Virology 1999; 9: 15-21. A43 Schiffman MH, Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia, Journal of the National Cancer Institute 1992; 84(6): 394-8. A44 Silins et al., Serological evidence for protection by human papillomarvirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis, Journal of General Virology 1999; 80: 2931-6. A45 Slawson et al., Follow up papanicolau smear for cervical atypia: are we missing significant disease? A HARNET study, Journal of Family practice 1993; 36(3): 289-93. A46 Soini et al., Presence of human papillomavirus DNA and abnormal p53 protein accumulation in lung carcinoma, Thorax 1996; 51: 887-93. A47 Sugase et al., Distinct manifestations of human papillomavirus in the vagina, International Journal of Cancer 1997; 72: 412-5. A48 Sun et al., Serum antibodies to human papillomavirus 16 proteins in women from Brazil with invasive cervical carcinoma, Cancer Epidemiology, Biomarkers & Prevention 1999; 8: 935-40. A49 Verdon ME, Issues in the management of human papillomavirus genital disease, American Family Physician 1997; 55: 1813-16. A50 Walboomers et al., Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, Journal of Pathology 1999; 189: 12-19. A51 Wright et al., HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer, Journal of the American Medical Association 2000; 283: 81-6. | A. | 7 | A40 | |
| Review of Medical Virology 1999; 9: 15-21. A43 Schiffman MH, Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia, Journal of the National Cancer Institute 1992; 84(6): 394-8. A44 Silins et al., Serological evidence for protection by human papillomarvirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis, Journal of General Virology 1999; 80: 2931-6. A45 Slawson et al., Follow up papanicolau smear for cervical atypia: are we missing significant disease? A HARNET study, Journal of Family practice 1993; 36(3): 289-93. A46 Soini et al., Presence of human papillomavirus DNA and abnormal p53 protein accumulation in lung carcinoma, Thorax 1996; 51: 887-93. A47 Sugase et al., Distinct manifestations of human papillomavirus in the vagina, International Journal of Cancer 1997; 72: 412-5. A48 Sun et al., Serum antibodies to human papillomavirus 16 proteins in women from Brazil with invasive cervical carcinoma, Cancer Epidemiology, Biomarkers & Prevention 1999; 8: 935-40. A49 Verdon ME, Issues in the management of human papillomavirus genital disease, American Family Physician 1997; 55: 1813-16. A50 Walboomers et al., Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, Journal of Pathology 1999; 189: 12-19. A51 Wright et al., HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer, Journal of the American Medical Association 2000; 283: 81-6. A52 Zumbach et al., Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in patients with head-and-neck squamous-cell | | į | A41 | subtypes of cervical adenocarcinoma, American Journal of Pathology 2000; |
| papillomavirus infection and cervical neoplasia, Journal of the National Cancer Institute 1992; 84(6): 394-8. A44 Silins et al., Serological evidence for protection by human papillomarvirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis, Journal of General Virology 1999; 80: 2931-6. A45 Slawson et al., Follow up papanicolau smear for cervical atypia: are we missing significant disease? A HARNET study, Journal of Family practice 1993; 36(3): 289-93. A46 Soini et al., Presence of human papillomavirus DNA and abnormal p53 protein accumulation in lung carcinoma, Thorax 1996; 51: 887-93. A47 Sugase et al., Distinct manifestations of human papillomavirus in the vagina, International Journal of Cancer 1997; 72: 412-5. A48 Sun et al., Serum antibodies to human papillomavirus 16 proteins in women from Brazil with invasive cervical carcinoma, Cancer Epidemiology, Biomarkers & Prevention 1999; 8: 935-40. A49 Verdon ME, Issues in the management of human papillomavirus genital disease, American Family Physician 1997; 55: 1813-16. A50 Walboomers et al., Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, Journal of Pathology 1999; 189: 12-19. A51 Wright et al., HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer, Journal of the American Medical Association 2000; 283: 81-6. A52 Zumbach et al., Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in patients with head-and-neck squamous-cell | | / | A42 | |
| type 6 infection against HPV type 16 cervical carcinogenesis, Journal of General Virology 1999; 80: 2931-6. A45 Slawson et al., Follow up papanicolau smear for cervical atypia: are we missing significant disease? A HARNET study, Journal of Family practice 1993; 36(3): 289-93. A46 Soini et al., Presence of human papillomavirus DNA and abnormal p53 protein accumulation in lung carcinoma, Thorax 1996; 51: 887-93. A47 Sugase et al., Distinct manifestations of human papillomavirus in the vagina, International Journal of Cancer 1997; 72: 412-5. A48 Sun et al., Serum antibodies to human papillomavirus 16 proteins in women from Brazil with invasive cervical carcinoma, Cancer Epidemiology, Biomarkers & Prevention 1999; 8: 935-40. A49 Verdon ME, Issues in the management of human papillomavirus genital disease, American Family Physician 1997; 55: 1813-16. A50 Walboomers et al., Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, Journal of Pathology 1999; 189: 12-19. A51 Wright et al., HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer, Journal of the American Medical Association 2000; 283: 81-6. A52 Zumbach et al., Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in patients with head-and-neck squamous-cell | | | A43 | papillomavirus infection and cervical neoplasia, Journal of the National Cancer |
| significant disease? A HARNET study, Journal of Family practice 1993; 36(3): 289-93. A46 Soini et al., Presence of human papillomavirus DNA and abnormal p53 protein accumulation in lung carcinoma, Thorax 1996; 51: 887-93. A47 Sugase et al., Distinct manifestations of human papillomavirus in the vagina, International Journal of Cancer 1997; 72: 412-5. A48 Sun et al., Serum antibodies to human papillomavirus 16 proteins in women from Brazil with invasive cervical carcinoma, Cancer Epidemiology, Biomarkers & Prevention 1999; 8: 935-40. A49 Verdon ME, Issues in the management of human papillomavirus genital disease, American Family Physician 1997; 55: 1813-16. A50 Walboomers et al., Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, Journal of Pathology 1999; 189: 12-19. A51 Wright et al., HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer, Journal of the American Medical Association 2000; 283: 81-6. A52 Zumbach et al., Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in patients with head-and-neck squamous-cell | | | A44 | Silins et al., Serological evidence for protection by human papillomarvirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis, Journal of General Virology 1999; 80: 2931-6. |
| accumulation in lung carcinoma, Thorax 1996; 51: 887-93. A47 Sugase et al., Distinct manifestations of human papillomavirus in the vagina, International Journal of Cancer 1997; 72: 412-5. A48 Sun et al., Serum antibodies to human papillomavirus 16 proteins in women from Brazil with invasive cervical carcinoma, Cancer Epidemiology, Biomarkers & Prevention 1999; 8: 935-40. A49 Verdon ME, Issues in the management of human papillomavirus genital disease, American Family Physician 1997; 55: 1813-16. A50 Walboomers et al., Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, Journal of Pathology 1999; 189: 12-19. A51 Wright et al., HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer, Journal of the American Medical Association 2000; 283: 81-6. A52 Zumbach et al., Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in patients with head-and-neck squamous-cell | | | A45 | significant disease? A HARNET study, Journal of Family practice 1993; 36(3): |
| International Journal of Cancer 1997; 72: 412-5. A48 Sun et al., Serum antibodies to human papillomavirus 16 proteins in women from Brazil with invasive cervical carcinoma, Cancer Epidemiology, Biomarkers & Prevention 1999; 8: 935-40. A49 Verdon ME, Issues in the management of human papillomavirus genital disease, American Family Physician 1997; 55: 1813-16. A50 Walboomers et al., Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, Journal of Pathology 1999; 189: 12-19. A51 Wright et al., HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer, Journal of the American Medical Association 2000; 283: 81-6. A52 Zumbach et al., Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in patients with head-and-neck squamous-cell | | | A46 | |
| Brazil with invasive cervical carcinoma, Cancer Epidemiology, Biomarkers & Prevention 1999; 8: 935-40. A49 Verdon ME, Issues in the management of human papillomavirus genital disease, American Family Physician 1997; 55: 1813-16. A50 Walboomers et al., Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, Journal of Pathology 1999; 189: 12-19. A51 Wright et al., HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer, Journal of the American Medical Association 2000; 283: 81-6. A52 Zumbach et al., Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in patients with head-and-neck squamous-cell | | | A47 | |
| American Family Physician 1997; 55: 1813-16. A50 Walboomers et al., Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, Journal of Pathology 1999; 189: 12-19. A51 Wright et al., HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer, Journal of the American Medical Association 2000; 283: 81-6. A52 Zumbach et al., Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in patients with head-and-neck squamous-cell | | | A48 | |
| cervical cancer worldwide, Journal of Pathology 1999; 189: 12-19. Wright et al., HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer, Journal of the American Medical Association 2000; 283: 81-6. A52 Zumbach et al., Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in patients with head-and-neck squamous-cell | | | A49 | Verdon ME, Issues in the management of human papillomavirus genital disease, American Family Physician 1997; 55: 1813-16. |
| cytologic screening to detect cervical cancer, Journal of the American Medical Association 2000; 283: 81-6. A52 Zumbach et al., Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in patients with head-and-neck squamous-cell | | / | A50 | |
| papillomavirus types 16 and 18 in patients with head-and-neck squamous-cell | | | A51 | cytologic screening to detect cervical cancer, Journal of the American Medical |
| | | | A52 | |

Z-YALL CLIENTS\3352 Impect Diagnostics\3352-2-2\3352-2-2 PAT-FIL-IDS 1449 040129.wpd

| 11/24/04 | EXAMINER DATE CONSIDERED | 11/29/04 |
|----------|--------------------------|----------|
|----------|--------------------------|----------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).